Fluticasone propionate/formoterol fumarate combination therapy has comparable efficacy to its individual components administered concurrently

A. Bodzenta-Lukaszyk, J. A. van Noord, W. G. Schröder-Babo, K. McAulay, T. McIver (Bialystok, Poland; Heerlen, Netherlands; Gelnhausen, Germany; Cambridge, United Kingdom)

Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Session: Airways disease comorbidities and general aspects
Session type: Thematic Poster Session
Number: 4007
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Bodzenta-Lukaszyk, J. A. van Noord, W. G. Schröder-Babo, K. McAulay, T. McIver (Bialystok, Poland; Heerlen, Netherlands; Gelnhausen, Germany; Cambridge, United Kingdom). Fluticasone propionate/formoterol fumarate combination therapy has comparable efficacy to its individual components administered concurrently. Eur Respir J 2011; 38: Suppl. 55, 4007

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Fluticasone propionate/formoterol fumarate combination therapy is equally effective and well-tolerated when administered with or without a spacer device to patients with asthma
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Fluticasone propionate/formoterol fumarate combination therapy has superior efficacy to both fluticasone and formoterol alone
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Fluticasone propionate/formoterol fumarate combination therapy is more effective than fluticasone propionate alone in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Fluticasone propionate/formoterol fumarate combination therapy is as effective as fluticasone propionate/salmeterol xinafoate, but has a more rapid onset of action in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Asthma exacerbation with fluticasone propionate/formoterol fumarate combination therapy versus its individual components
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012

Long-term treatment with fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy is well-tolerated and provides sustained effectiveness in paediatric patients with asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011


Fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy has comparable efficacy to fluticasone propionate/salmeterol xinafoate (FLUT/SAL) in paediatric patients with asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011


Effect of treatment with mometasone furoate/formoterol combination on rescue medication use
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010


Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

Efficacy and safety of combined mometasone furoate/formoterol 100/10μg twice daily in subjects with asthma inadequately controlled on low-dose inhaled corticosteroids
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010


The salmeterol/fluticasone propionate combination 50/100 μg b.i.d is effective as initial maintenance therapy in mild and moderate asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001

LATE-BREAKING ABSTRACT: ENERGITO: Efficacy and safety of once-daily combined tiotropium + olodaterol versus twice-daily combined fluticasone propionate + salmeterol
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015


Once daily ciclesonide and twice daily fluticasone propionate are equally effective in the treatment of patients with asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 346s
Year: 2004

Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010


Comparison of the fine particle fraction of fluticasone propionate/formoterol fumarate combination with other combination products
Source: Annual Congress 2012 - Mechanics, muscles and movement: aspects of airway mechanics, repiratory muscle assessment and field exercise tests
Year: 2012

Effect of combination fluticasone propionate and salmeterol diskhaler in treatment of moderate to severe asthma: comparison of initial high dose, constant medium dose and placebo
Source: Eur Respir J 2001; 18: Suppl. 33, 123s
Year: 2001

Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010


Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011

Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004